- Novo Nordisk shares stoop as weight-loss drug trial information disappoints Financial Times
- Novo Nordisk shares plunge 22% after CagriSema weight problems drug trial outcomes CNBC
- Novo Nordisk’s next-gen weight problems drug CagriSema achieves decrease weight reduction than anticipated Reuters.com
- Novo Nordisk Stock Crashes 22% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar. Barron’s
- Novo Nordisk’s Shares Tank After Experimental Obesity Shot Misses Target The Wall Street Journal